home / stock / pvct / pvct news

PVCT News and Press, Provectus Biopharmaceuticals Inc From 08/24/22

Stock Information
Company Name: Provectus Biopharmaceuticals Inc
Stock Symbol: PVCT
Market: OTC
Website: provectusbio.com
Menu
PVCT PVCT Quote PVCT Short PVCT News PVCT Articles PVCT Message Board
Get PVCT Alerts

News, Short Squeeze, Breakout and More Instantly...
PVCT - Provectus Biopharma partners to test rose bengal as anti-fungal and anti-oral bacterial agent

Provectus ( OTC:PVCT ) said it had expanded its sponsored research program with Michio Kurosu, Professor at the University of Tennessee Health Science Center to investigate its pharmaceutical-grade rose bengal to treat anti-fungal and anti-oral bacterial infections. The Kurosu...
PVCT - Provectus Biopharmaceuticals Expands Sponsored Research Collaboration with University of Tennessee Health Science Center to Investigate Pharmaceutical-Grade Rose Bengal as Anti-Fungal and Anti-Oral Bacterial Agent

KNOXVILLE, TN, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company has expanded its sponsored research program with Michio Kurosu, PhD, Professor, Department of Pharmaceutical Sciences at the College of Pharmacy of the University of Tennessee Health Sc...

PVCT - Provectus Biopharmaceuticals Expands Sponsored Research Collaboration with University of Calgary (Canada) to Investigate Systemic Administration of Pharmaceutical-Grade Rose Bengal for Treatment of Pediatric Leukemia

KNOXVILLE, TN, Aug. 17, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company has expanded its sponsored research program with Aru Narendran, MD, PhD, Professor, Departments of Pediatrics, Oncology, Biochemistry & Molecular Biology, and Physiology & Pharm...

PVCT - Provectus Biopharmaceuticals Establishes Research Collaboration with University of Nevada, Las Vegas to Investigate Small Molecule Immunotherapy Rose Bengal for Tissue Regeneration and Repair

KNOXVILLE, TN, July 19, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company has initiated a new sponsored research program with Kelly Tseng, PhD, Associate Professor of Pathology and Lab Medicine, School of Life Sciences at the University of Nevada, Las Vegas (...
PVCT - Provectus Biopharmaceuticals Presents Data from PV-10® Treatment of Metastatic Uveal Melanoma Patients in Two Oral Presentations at 2022 International Society of Ocular Oncology (ISOO) Congress

KNOXVILLE, TN, June 30, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that updated data from the Company’s initial expansion cohort of patients with uveal melanoma metastatic to the liver (mUM) in its cancers-of-the-liver Phase 1 trial of investigational immunocata...

PVCT - Provectus receives shareholders approval to go for reverse stock splits

Provectus (OTC:PVCT) stated Thursday it has received shareholders approval to execute reverse stock splits of its common and preferred shares in the same ratio along with the authorized share reduction. The reverse stock split is to be effected at a ratio of between 1-for-10 an...

PVCT - Provectus Biopharmaceuticals Announces Stockholder Approval to Undertake Reverse Split of Outstanding Equities and Reduce Number of Authorized Equities by Same Ratio

KNOXVILLE, TN, June 23, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company’s shareholders have approved the proposals of Provectus’ Board of Directors (Board) to seek the authority to undertake a reverse stock split and an authorized share reduct...
PVCT - Provectus Biopharmaceuticals Presents Multiple Metabolic Complete Responders from PV-10® Treatment of Early-Stage Metastatic Uveal Melanoma Patients at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

29% of M1a patients achieved metabolic complete response (mCR) mCR patients alive up to >4 years after start of PV-10 treatment PET tumor response assessment more accurate than 2D EASL or RECIST PV-10 combination therapy with checkpoint blockade may offer durable respo...

PVCT - Provectus to get US patent for topical PH-10 to treat certain skin conditions

Provectus (OTC:PVCT) said the U.S. Patent and Trademark Office (USPTO) allowed a patent application covering the use of topical PH-10 to treat certain inflammatory skin conditions. The company said the U.S. patent application 16/204,832, is titled 'Combination of local and systemic ...

PVCT - Provectus Biopharmaceuticals Announces Notice of Allowance of First U.S. Patent of PH-10 Immuno-Dermatology Agent for Treatment of Inflammatory Dermatoses and Epithelial Diseases

KNOXVILLE, TN, May 03, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the United States Patent and Trademark Office (USPTO) has allowed US patent (USP) application 16/204,832, “ Combination of local and systemic therapies for enhanced treatment of dermatologi...
Previous 10 Next 10